Cite
Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial.
MLA
Yoneda, Masato, et al. “Combination of Tofogliflozin and Pioglitazone for NAFLD: Extension to the ToPiND Randomized Controlled Trial.” Hepatology Communications, vol. 6, no. 9, Sept. 2022, pp. 2273–85. EBSCOhost, https://doi.org/10.1002/hep4.1993.
APA
Yoneda, M., Kobayashi, T., Honda, Y., Ogawa, Y., Kessoku, T., Imajo, K., Nogami, A., Taguri, M., Kirikoshi, H., Saito, S., & Nakajima, A. (2022). Combination of tofogliflozin and pioglitazone for NAFLD: Extension to the ToPiND randomized controlled trial. Hepatology Communications, 6(9), 2273–2285. https://doi.org/10.1002/hep4.1993
Chicago
Yoneda, Masato, Takashi Kobayashi, Yasushi Honda, Yuji Ogawa, Takaomi Kessoku, Kento Imajo, Asako Nogami, et al. 2022. “Combination of Tofogliflozin and Pioglitazone for NAFLD: Extension to the ToPiND Randomized Controlled Trial.” Hepatology Communications 6 (9): 2273–85. doi:10.1002/hep4.1993.